Immunoassay for pyruvate kinase M1/2 as an Alzheimer’s biomarker in CSF

Immunoassay for pyruvate kinase M1/2 as an Alzheimer’s biomarker in CSF

Alzheimer’s disease (AD) is characterized by amyloid-beta plaques and tau tangles in the brain, but these markers alone do not predict disease progression. The intersection of these pathologies with other processes including metabolic changes may contribute to disease progression. Brain glucose meta...

Full description

Saved in:
Bibliographic Details
Main Authors: de Geus Matthijs B., Kivisäkk Pia, Trombetta Bianca A., Tijms Betty M., Visser Pieter Jelle, Arnold Steven E., Carlyle Becky C.
Format: Article
Language:English
Published: De Gruyter 2025-07-01
Series:Open Life Sciences
Subjects:
alzheimer’s disease
pyruvate kinase
biomarker
glucose metabolism
immunoassay
Online Access:https://doi.org/10.1515/biol-2025-1101
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1515/biol-2025-1101

Similar Items